105
after complete vs. incomplete revascularization of patients with multivessel coronary artery disease:
a meta-analysis of 89,883 patients enrolled in randomized clinical trials and observational studies. J
Am Coll Cardiol 2013;62(16):1421 – 1431.
95.
Taggart DP, Lees B, Gray A, Altman DG, Flather M, Channon K, Investigators ART. Protocol for
the Arterial Revascularisation Trial (ART).A randomised trial to compare survival following bilateral
vs. single internal mammary grafting in coronary revascularisation [ISRCTN46552265]. Trials
2006;7:7.
96.
Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, Straka Z, Piegas LS, Akar
AR, Jain AR, Noiseux N, Padmanabhan C, Bahamondes JC, Novick RJ, Vaijyanath P, Reddy SK,
Tao L, Olavegogeascoechea PA, Airan B, Sulling TA, Whitlock RP, Ou Y, Pogue J, Chrolavicius S,
Yusuf S, Investigators C. Effects of off-pump and on-pump coronaryartery bypass grafting at 1 year.
N Engl J Med 2013;368(13):1179–1188.
97.
Shroyer AL, Grover FL, Hattler B, Collins JF, McDonald GO, Kozora E, Lucke JC, Baltz JH,
Novitzky D. On-pump vs. off-pump coronary-artery bypass surgery. N Engl J Med
2009;361(19):1827–1837.
98.
Sergeant P, Blackstone E, Meyns B. Validation and interdependence with patient variables of the
influence of procedural variables on early and late survival after CABG. K.U. Leuven Coronary
Surgery Program. Eur J Cardiothorac Surg 1997; 12(1):1 – 19.
99.
Desai ND, Cohen EA, Naylor CD, Fremes SE. A Randomized Comparison of Radial-Artery and
Saphenous-Vein Coronary Bypass Grafts. N Engl J Med 2004; 351:2302 – 2309.
100.
Tatoulis J. Total arterial coronary revascularization-patient selection, stenoses, conduits, targets. Ann
Cardiothorac Surg 2013;2(4):499–506.
101.
Borgermann J, Hakim K, Renner A, Parsa A, Aboud A, Becker T, Masshoff M, Zittermann A,
Gummert JF, Kuss O. Clampless off-pump vs. conventional coronary artery revascularization: a
propensity score analysis of 788 patients. Circulation 2012;126(11 Suppl 1):S176–182.
102.
Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-
analysis. Ann Intern Med 2003;138(10):777–786.
103.
PlanerD,SmitsPC,KereiakesDJ,KedhiE,FahyM,XuK,SerruysPW,StoneGW.
Comparison
of
everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled
results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent
System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for
Coronary Revascularization in Daily Practice) Trials. JACC Cardiovasc Interv 2011;4(10):1104 –
1115.
104.
Verheye S, Agostoni P, Dubois CL, Dens J, Ormiston J, Worthley S, Trauthen B, Hasegawa T, Koo
BK, Fitzgerald PJ, Mehran R, Lansky AJ. 9-month clinical, angiographic, and intravascular
ultrasound results of a prospective evaluation of the Axxess self-expanding biolimus A9-eluting stent
in coronary bifurcation lesions: the DIVERGE (Drug-Eluting Stent Intervention for Treating Side
Branches Effect- ively) study. J Am Coll Cardiol 2009;53(12):1031 – 1039.
105.
FischerD,SchellerB,SchaferA,KleinG,BohmM,CleverY,CremersB.Paclitaxcel coated balloon plus
bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study. EuroIntervention
2012;8(4):450 – 455.
106.
Christofferson RD, Lehmann KG,
Martin GV, Every N, Caldwell JH, Kapadia SR.
Effect of chronic
total coronary occlusion on treatment strategy. Am J Cardiol 2005;95(9):1088 – 1091.
107.
Lee SW, Kim SH, Kim SO, Han S, Kim YH, Park DW, Kang SJ, Lee CW, Park SW, Park SJ.
Comparative long-term efficacy and safety of drug-eluting stent vs. coronary artery bypass grafting
in ostial left main coronary artery disease: analysis of the MAIN-COMPARE registry. Catheter
Cardiovasc Interv 2012;80(2):206 – 212.
108.
Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J,